Hamps Bio

Why is Hamps Bio Limited falling/rising?

As of 18-Jul, Hamps Bio Limited's stock price is stable at 25.10 but has declined by 1.65% over the past week and 2.90% over the past month, underperforming against the Sensex. Despite a strong year-to-date increase of 25.50%, recent trading activity and a significant drop in investor participation indicate potential challenges for the stock's immediate price momentum.

As of 18-Jul, Hamps Bio Limited's stock price is currently stable at 25.10, with no change from the previous trading session. Despite this stability, the stock has experienced a decline in performance over the past week and month, with decreases of 1.65% and 2.90%, respectively. In contrast, the benchmark Sensex has shown positive returns of 0.75% over the past week and 1.29% over the past month, indicating that Hamps Bio Limited is underperforming relative to the market.<BR><BR>Year-to-date, the stock has seen a significant increase of 25.50%, which contrasts sharply with the Sensex's decline of 8.30%. Over the past year, Hamps Bio Limited has also outperformed the benchmark, rising by 31.45% compared to the Sensex's drop of 4.99%. However, recent trading activity has been erratic, with the stock not trading on three days out of the last twenty, which may indicate a lack of consistent investor interest.<BR><BR>Additionally, there has been a notable decrease in investor participation, as evidenced by a 50% drop in delivery volume on July 15 compared to the five-day average. This decline in trading volume could contribute to the stock's inability to gain upward momentum despite its strong year-to-date and yearly performance. The moving averages suggest that while the stock is above the 50-day, 100-day, and 200-day moving averages, it is below the 5-day and 20-day averages, which may reflect short-term weakness.<BR><BR>Overall, while Hamps Bio Limited has shown strong long-term performance, recent trends in trading volume and relative underperformance against the benchmark suggest that the stock is facing challenges that could hinder its price from rising in the immediate term.

Which are the latest news on Hamps Bio?

What does Hamps Bio do?

Hamps Bio Limited is a Micro Cap company in the Other Agricultural Products industry, incorporated in 2007 and rebranded in 2023. It currently has a market cap of INR 23 Cr, with no available revenue or profit data for the latest quarter.

Overview:<BR>Hamps Bio Limited operates in the Other Agricultural Products industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Hamps Bio Limited was originally incorporated as "Hamps Bio Private Limited" in 2007. The company later changed its status to Public Limited and its name to "Hamps Bio Limited," with the latest Certificate of Incorporation issued on July 12, 2023. Revenue and profit data for the most recent quarter are not available.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 23 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A<BR>Industry P/E: 34<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.83<BR>Return on Equity: -91.23%<BR>Price-to-Book: 2.80<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the peers of the Hamps Bio?

Hamps Bio's peers include Prospect Consum., Alfavision Overs, Sunil Agro Foods, and others, with varying management risks and growth rates. Notably, Natura Hue Chem has the highest 1-year return at 277.77%, while Hamps Bio's return is 20.23%.

Peers: The peers of Hamps Bio are Prospect Consum., Alfavision Overs, Sunil Agro Foods, Times Green Ener, TGIF Agribusines, Vikas Wsp, Annvrridhhi Ven, Natura Hue Chem, and Continental Seed.<BR><BR>Quality Snapshot: Excellent management risk is observed at TGIF Agribusines, while Average management risk is found at Prospect Consum. and Sunil Agro Foods, and the rest. Below Average management risk is noted at Alfavision Overs, Times Green Ener, Vikas Wsp, Annvrridhhi Ven, Continental Seed, and the rest. Growth is Excellent at TGIF Agribusines, Average at Annvrridhhi Ven, and Below Average at Alfavision Overs, Sunil Agro Foods, Hamps Bio, Vikas Wsp, and the rest. Capital Structure is Good at Prospect Consum. and Times Green Ener, Average at Continental Seed, and Below Average at Alfavision Overs, Sunil Agro Foods, Hamps Bio, Vikas Wsp, Annvrridhhi Ven, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Natura Hue Chem at 277.77%, while the lowest is Prospect Consum. at -38.86%. Hamps Bio's 1-year return of 20.23% is significantly higher than that of Prospect Consum. Additionally, peers with negative six-month returns include Prospect Consum., Sunil Agro Foods, Vikas Wsp, Annvrridhhi Ven, and Continental Seed.

When is the next results date for Hamps Bio Limited?

The next results date for Hamps Bio Limited is 29 May 2026.

The next results date for Hamps Bio Limited is scheduled for 29 May 2026.

How has been the historical performance of Hamps Bio?

Hamps Bio has experienced steady revenue growth, with net sales increasing from 5.58 Cr in Mar'23 to 6.67 Cr in Mar'25, but profitability has declined, with profit after tax dropping from 0.50 Cr in Mar'24 to 0.30 Cr in Mar'25. Despite fluctuations in operating profit and rising costs, the company's equity capital and book value per share have improved, indicating a stronger financial position.

Answer:<BR>The historical performance of Hamps Bio shows a mixed trend in its financial metrics over the past three years.<BR><BR>Breakdown:<BR>Hamps Bio's net sales have increased from 5.58 Cr in Mar'23 to 6.67 Cr in Mar'25, indicating a steady growth in revenue. However, the total operating income has also risen in tandem, reflecting consistent performance. The raw material costs have surged to 0.85 Cr in Mar'25 from 0.21 Cr in Mar'23, while the purchase of finished goods decreased slightly to 2.01 Cr in Mar'25 from 2.17 Cr in Mar'24. Employee costs have risen, contributing to an overall increase in total expenditure, which reached 5.90 Cr in Mar'25 compared to 4.71 Cr in Mar'23. Operating profit (PBDIT) has shown fluctuations, peaking at 1.21 Cr in Mar'24 but dropping to 0.92 Cr in Mar'25. Profit before tax has also decreased from 0.65 Cr in Mar'24 to 0.40 Cr in Mar'25, leading to a profit after tax of 0.30 Cr in Mar'25, down from 0.50 Cr in Mar'24. The company's equity capital has significantly increased to 4.36 Cr in Mar'25 from 1.50 Cr in Mar'23, while total liabilities have risen to 12.67 Cr in Mar'25 from 3.61 Cr in Mar'22. The book value per share has improved to 20.2 in Mar'25 from 4.1875 in Mar'22, indicating a strengthening financial position despite the recent declines in profitability.

Is Hamps Bio overvalued or undervalued?

As of September 9, 2025, Hamps Bio is considered very expensive and overvalued with a PE ratio of 13.07 and an EV to EBITDA of 15.94, significantly lagging behind peers like Sun Pharma and Cipla, while also experiencing a year-to-date return of -27.42% compared to the Sensex's 3.79% gain.

As of 9 September 2025, Hamps Bio's valuation grade has moved from expensive to very expensive, indicating a significant shift in its market perception. The company is currently considered overvalued based on its financial ratios. The PE ratio stands at 13.07, while the EV to EBITDA ratio is 15.94, and the ROE is a mere 3.41%. <BR><BR>In comparison to its peers, Hamps Bio's valuation metrics are notably less favorable; for instance, Sun Pharma has a PE ratio of 33.36 and an EV to EBITDA of 22.55, while Cipla, rated as attractive, has a PE of 23.28 and an EV to EBITDA of 16.4. This stark contrast highlights Hamps Bio's overvaluation in the current market context. Additionally, the company's recent stock performance has been underwhelming, with a year-to-date return of -27.42%, contrasting sharply with the Sensex's 3.79% gain.

What is the bonus history of Hamps Bio?

Hamps Bio recently announced a 1:1 bonus issue, granting shareholders an additional share for each share held, with an ex-date and record date of September 8, 2025.

Hamps Bio has a recent bonus issue where they announced a 1:1 bonus. This means that for every share held, shareholders will receive an additional share. The ex-date for this bonus issue is September 8, 2025, which is also the record date. This is the latest information regarding their bonus history. If you have any more questions about Hamps Bio or need further details, feel free to ask!

What is the technical trend for Hamps Bio?

As of May 29, 2025, Hamps Bio's technical trend is mildly bearish, indicated by the Dow Theory and a lack of bullish signals in the MACD, with the price near its 52-week low and a year-to-date decline of 50.65%.

As of 29 May 2025, the technical trend for Hamps Bio has changed from sideways to mildly bearish. The weekly Dow Theory indicates a mildly bearish stance, and the MACD shows no signal on the weekly and monthly charts. The Bollinger Bands are sideways on the weekly timeframe, suggesting a lack of volatility. The current price is near the lower end of its 52-week range, with a significant decline of 50.65% year-to-date compared to a positive return from the Sensex. Overall, the technical stance is mildly bearish, driven primarily by the Dow Theory and the lack of bullish signals in the MACD.

Who are the top shareholders of the Hamps Bio?

The top shareholders of Hamps Bio are mainly promoters, with Herrik Mountbaton Shah holding the largest share at 31.12%. Individual investors own 24.66% of the shares, while there are no holdings from mutual funds or foreign institutional investors.

The top shareholders of Hamps Bio are primarily the promoters, with Herrik Mountbaton Shah being the individual with the highest holding at 31.12%. Additionally, individual investors collectively hold 24.66% of the company's shares. There are currently no holdings from mutual funds or foreign institutional investors.

how big is Hamps Bio?

As of Jun 06, Hamps Bio Limited has a market capitalization of 18.00 Cr, classifying it as a Micro Cap company. There is no available financial data for the latest four quarters, with shareholder's funds at 3.37 Cr and total assets of 5.10 Cr as of March 2024.

Market Cap: As of Jun 06, Hamps Bio Limited has a market capitalization of 18.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid Consolidated or Standalone financial data available for the latest four quarters, including Net Sales and Net Profit.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the reporting period of March 2024. Shareholder's Funds are reported at 3.37 Cr, and Total Assets amount to 5.10 Cr.

Has Hamps Bio declared dividend?

No Dividend History Available